Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections - A Look At Korea (Part 3)

South Korea's pharmaceutical regulatory program is in a state of change, and the Korea FDA is open to ongoing changes to support regulatory harmonization with the rest of the world. That openness presents an opportunity for industry to influence some differences between Korea and the rest of the world, according to said Jeffrey Ferguson, Eli Lilly's director of global regulatory affairs CMC